Theragent
Private Company
Total funding raised: $3M
Overview
Theragent is a privately held, US-based CDMO founded in 2018, serving the high-growth cell and gene therapy (CGT) sector. It offers end-to-end services from early-stage R&D through clinical and commercial manufacturing, leveraging its state-of-the-art facilities and a management team with deep expertise in oncology, process development, and GMP operations. As a service provider, its financial model is based on client contracts, positioning it in the 'Revenue Generating' stage within the specialized CGT services market.
Technology Platform
Integrated CDMO platform for cell and gene therapies, offering end-to-end services from R&D (primary cell culture, engineering, assays) through process development, analytical development, cGMP clinical manufacturing, quality control, regulatory affairs, and supply chain management.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Theragent competes in the fragmented but consolidating CGT CDMO space against large global players (e.g., Lonza, Catalent, Thermo Fisher's Patheon), established bioprocessing leaders (e.g., Samsung Biologics, Fujifilm Diosynth), and a growing number of specialized pure-play CGT CDMOs (e.g., Oxford Biomedica, Cellular Therapeutics, ElevateBio). Its differentiation hinges on its integrated platform, specialized expertise, and West Coast proximity to clients.